1-(t-丁氧羰基)吡唑-5-硼酸 | 1217500-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(t-丁氧羰基)吡唑-5-硼酸
• 中文别名: 1-(T-丁氧基羰基)吡唑-5-硼酸
• 英文名称: (1-(tert-butoxycarbonyl)-1H-pyrazol-5-yl)boronic acid
• 英文别名: (2-tert-butoxycarbonylpyrazol-3-yl)boronic acid；[2-[(2-methylpropan-2-yl)oxycarbonyl]pyrazol-3-yl]boronic acid
• CAS: 1217500-54-3
• 化学式: C₈H₁₃BN₂O₄
• 分子量: 212.013
• InChiKey: BMAIJKCROWPJPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.65
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(t-Butoxycarbonyl)pyrazole-5-boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(t-Butoxycarbonyl)pyrazole-5-boronic acid
CAS number: 1217500-54-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H13BN2O4
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-diphenyl-3-hydroxypropene 、 1-(t-丁氧羰基)吡唑-5-硼酸 以 水 为溶剂， 反应 9.0h， 以72%的产率得到1-(1,3-diphenylallyl)-1H-pyrazole
  参考文献：
  名称：

  富电子的杂芳基硼酸与烯丙基醇的无金属烯丙基化

  摘要：

  描述了在无催化剂的反应条件下杂芳基硼酸与烯丙基醇的方便且区域选择性的交叉偶联。所开发的方法很简单，可以在无外部氧化剂和无金属的条件下工作，并且证明是非常通用的，具有空前的邻位选择性。该方法代表了硼酸的邻官能化的极少数实例之一。

  DOI：

  10.1016/j.tet.2016.02.047
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 4-二甲氨基吡啶 、 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 6.0h， 生成 1-(t-丁氧羰基)吡唑-5-硼酸
  参考文献：
  名称：

  一种1-（叔丁氧羰基）吡唑-5-硼酸的合成方法

  摘要：

  本发明涉及有机化合物的合成方法。一种合成1‑（叔丁氧羰基）吡唑‑5‑硼酸的方法。共两步反应：将吡唑与二碳酸二叔丁酯反应得到1‑叔丁氧羰基吡唑；再与正丁基锂和硼酸酯反应得到1‑（叔丁氧羰基）吡唑‑5‑硼酸。本发明合成方法尚未有文献报道，两步总收率60%以上。具有原创性，且原料易得、操作简便，可以放大，是一种制备1‑（叔丁氧羰基）吡唑‑5‑硼酸的适宜路径。

  公开号：

  CN117756833A

文献信息

• [EN] 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY<br/>[FR] HÉTÉROARYLAMINOSULFONAMIDES À 5 CHAÎNONS POUR LE TRAITEMENT D'ÉTATS À MÉDIATION PAR UNE ACTIVITÉ CFTR DÉFICIENTE
  申请人：GENZYME CORP

  公开号：WO2021097057A1

  公开（公告）日：2021-05-20

  The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

  这项发明涉及杂环芳基化合物，其药用盐以及药物制剂。本文还描述了这些化合物的组成以及在治疗由CFTR活性不足介导的疾病和病况的方法中的使用，特别是囊性纤维化。
• ANTIPROLIFERATION COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20190322658A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I′的化合物，或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES
  申请人：Ho Pil Su

  公开号：US20140315888A1

  公开（公告）日：2014-10-23

  The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.

  该发明涉及新型杂环化合物，用于制备治疗与组织胺4受体的各种功能相关的疾病的药物。特别是，所述药物适用于治疗炎症性疾病、过敏、疼痛、鼻息肉、鼻炎、慢性鼻窦炎、鼻塞、鼻痒、哮喘、慢性阻塞性肺病、类风湿性关节炎、特应性皮炎、牛皮癣、湿疹、瘙痒、瘙痒皮肤、荨麻疹、特发性慢性荨麻疹、硬皮病、结膜炎、角膜结膜炎、眼部炎症、干眼症、心脏功能障碍、心律失常、动脉粥样硬化、多发性硬化、炎症性肠病（包括结肠炎、克罗恩病、溃疡性结肠炎）、炎症性疼痛、神经痛、骨关节炎疼痛、自身免疫性甲状腺疾病、免疫介导（也称为I型）糖尿病、红斑狼疮、术后粘连、前庭障碍和癌症的药物治疗。
• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2013182612A1

  公开（公告）日：2013-12-12

  The present invention relates to chemical compounds of general formula (I): in which RA, RB, RC, RD, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及通式(I)的化合物：其中RA、RB、RC、RD、m和n如描述和权利要求中所述，并且有效地且选择性地抑制葡萄糖转运蛋白1（GLUT1），以及制备该化合物的方法，包括含有该化合物的药物组合物和药物组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物的用途，以及在制备该化合物中有用的中间体化合物。
• 吡唑并嘧啶化合物和药物组合物及其应用
  申请人：南京烁慧医药科技有限公司

  公开号：CN110734437B

  公开（公告）日：2022-04-08

  本发明涉及生物医药领域，公开了吡唑并嘧啶化合物和药物组合物及其应用，该吡唑并嘧啶化合物具有式(I)所示结构。本发明提供的具有式(I)所示结构的吡唑并嘧啶化合物或其药学上可接受的盐，或其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物，或其前药对TRK激酶表现出优异的抑制活性，同时，在动物水平上表现出良好的抗肿瘤活性。